MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-25-2026
Armata Pharmaceuticals ROE Ratio 2011-2026 | ARMP
Annual ROE Ratio Armata Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.51 | 39.39 | 215.33 | -102.32 | -91.17 | -117.63 | -133.48 | -142.91 | -166.06 | -193.75 | -4.06 | 672.36 | 410.74 | -8.58 | -53.01 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 672.36 | -193.75 | 26.96 |
Quarterly ROE Ratio Armata Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.25 | 57.09 | 14.16 | 35.54 | 287.12 | 527.95 | 528.91 | 168.5 | 149.6 | -120.88 | -119.64 | -50.45 | -73.26 | -77.17 | -81.52 | -60.61 | -91.2 | -98.99 | -102.32 | -82.5 | -130.16 | -147.23 | -151.02 | -102.06 | -138.07 | -126.43 | -138.81 | -114.16 | -124.24 | -98.3 | -140.71 | -135.64 | -233.34 | -247.69 | -203.73 | -193.75 | -113.59 | -93.22 | -57.67 | -29.72 | -31.49 | 644.92 | 1321.34 | 1997.76 | 2302.53 | 1915.62 | 1528.71 | 856.35 | 856.35 | 570.9 | 285.45 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2302.53 | -247.69 | 204.19 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.88 | -1.73 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.48 | 0.81 % | $ 3.73 B | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
-86.96 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
22.71 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 101.39 | -0.66 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.06 | -0.98 % | $ 434 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.08 | -1.45 % | $ 2.94 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.92 | -0.14 % | $ 4.81 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.7 | -1.45 % | $ 114 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
529.06 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 1.06 | -3.21 % | $ 12.9 M | USA |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 2.83 | -2.92 % | $ 284 M | USA |